<?xml version="1.0" encoding="UTF-8"?>
<p id="Par101">Regarding RSV, the prophylactic use of palivizumab (monoclonal antibody against RSV) in young children undergoing HSCT was recommended in the 2009 international guidelines to prevent infective complications; however, the lack of clear evidences on its efficacy has limited the application of this measure [
 <xref ref-type="bibr" rid="CR29">29</xref>].
</p>
